SRP	ACCESSION	RUN_SET.RUN.IDENTIFIERS.PRIMARY_ID	SAMPLE.SAMPLE_NAME.TAXON_ID	Pool.Member.@sample_title	replicate	infection	sequencing_library_method	lab_host	passage_history	serotype	case history of originator	genotype/variation	timepoint_days_post_infection	stress	polysome fraction	biological replicates	barcode	isolation_source	knockdown	age	note	donor id	cell line background	reference genome	source_name	disease	treatment	tissue	genotype	genetics	overexpression	tumor type	isolate	geo_loc_name	chip antibody	time	ectopic e2f-1 expressed	treatment2	genetic aberration	shRNA	treated with	concentration	sample_type	agent	time point	cell line	tissue source	treatment1	BioSampleModel	antibody	collection_date	mtap status	incubation time	vector	conditions	transfection	condition	cell type	culture type	time of treatment
SRP310288	SRX10322196	SRR13943156	9606	Vector1							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														Vector, JHH-7 cells		Empty vector transfection		control																	HCC cell line JHH-7														
SRP310288	SRX10322197	SRR13943157	9606	Vector2							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														Vector, JHH-7 cells		Empty vector transfection		control																	HCC cell line JHH-7														
SRP310288	SRX10322198	SRR13943158	9606	Vector3							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														Vector, JHH-7 cells		Empty vector transfection		control																	HCC cell line JHH-7														
SRP310288	SRX10322199	SRR13943159	9606	shPRMT5_1							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														shPRMT5, JHH-7 cells		PRMT5 shRNA transfection		PRMT5 knockdown																	HCC cell line JHH-7														
SRP310288	SRX10322200	SRR13943160	9606	shPRMT5_2							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														shPRMT5, JHH-7 cells		PRMT5 shRNA transfection		PRMT5 knockdown																	HCC cell line JHH-7														
SRP310288	SRX10322201	SRR13943161	9606	shPRMT5_3							HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis. HBs-Ag(+), HBs-Ab(-), HBe-Ag(-), HBe-Ab(+), HBc-Ab(+), AFP positive (110,000 ng/ml).														shPRMT5, JHH-7 cells		PRMT5 shRNA transfection		PRMT5 knockdown																	HCC cell line JHH-7														
SRP319164	SRX10828151	SRR14479966	9606	RNA-seq_MCF7_1																					parental MCF7		untreated																			MCF7														
SRP319164	SRX10828152	SRR14479967	9606	RNA-seq_MCF7_2																					parental MCF7		untreated																			MCF7														
SRP319164	SRX10828153	SRR14479968	9606	RNA-seq_MCF7-DR_1																					doxorubicin-resistant MCF7 (MCF7-DR)		treated with 1 μM doxorubicin hydrochloride																			MCF7-DR														
SRP319164	SRX10828154	SRR14479969	9606	RNA-seq_MCF7-DR_2																					doxorubicin-resistant MCF7 (MCF7-DR)		treated with 1 μM doxorubicin hydrochloride																			MCF7-DR														
SRP319164	SRX10828155	SRR14479970	9606	ATAC-seq_MCF7_1																					parental MCF7		untreated																			MCF7														
SRP319164	SRX10828156	SRR14479971	9606	ATAC-seq_MCF7_2																					parental MCF7		untreated																			MCF7														
SRP319164	SRX10828157	SRR14479972	9606	ATAC-seq_MCF7-DR_1																					doxorubicin-resistant MCF7 (MCF7-DR)		treated with 1 μM doxorubicin hydrochloride																			MCF7-DR														
SRP319164	SRX10828158	SRR14479973	9606	ATAC-seq_MCF7-DR_2																					doxorubicin-resistant MCF7 (MCF7-DR)		treated with 1 μM doxorubicin hydrochloride																			MCF7-DR														
SRP320300	SRX10918588	SRR14575418	9606	H1975_DMSO_1	1																				Cancer cell line		DMSO																			H1975														
SRP320300	SRX10918589	SRR14575419	9606	H1975_DMSO_2	2																				Cancer cell line		DMSO																			H1975														
SRP320300	SRX10918590	SRR14575420	9606	H1975_DMSO_3	3																				Cancer cell line		DMSO																			H1975														
SRP320300	SRX10918591	SRR14575421	9606	H1975_PRMT5i_1	1																				Cancer cell line		PRMT5i																			H1975														
SRP320300	SRX10918592	SRR14575422	9606	H1975_PRMT5i_2	2																				Cancer cell line		PRMT5i																			H1975														
SRP320300	SRX10918593	SRR14575423	9606	H1975_PRMT5i_3	3																				Cancer cell line		PRMT5i																			H1975														
SRP320300	SRX10918594	SRR14575424	9606	A427_DMSO_1	1																				Cancer cell line		DMSO																			A427														
SRP320300	SRX10918595	SRR14575425	9606	A427_DMSO_2	2																				Cancer cell line		DMSO																			A427														
SRP320300	SRX10918596	SRR14575426	9606	A427_DMSO_3	3																				Cancer cell line		DMSO																			A427														
SRP320300	SRX10918597	SRR14575427	9606	A427_PRMT5i_1	1																				Cancer cell line		PRMT5i																			A427														
SRP320300	SRX10918598	SRR14575428	9606	A427_PRMT5i_2	2																				Cancer cell line		PRMT5i																			A427														
SRP320300	SRX10918599	SRR14575429	9606	A427_PRMT5i_3	3																				Cancer cell line		PRMT5i																			A427														
SRP320300	SRX10918600	SRR14575430	9606	H441_DMSO_1	1																				Cancer cell line		DMSO																			H441														
SRP320300	SRX10918601	SRR14575431	9606	H441_DMSO_2	2																				Cancer cell line		DMSO																			H441														
SRP320300	SRX10918602	SRR14575432	9606	H441_DMSO_3	3																				Cancer cell line		DMSO																			H441														
SRP320300	SRX10918603	SRR14575433	9606	H441_PRMT5i_1	1																				Cancer cell line		PRMT5i																			H441														
SRP320300	SRX10918604	SRR14575434	9606	H441_PRMT5i_2	2																				Cancer cell line		PRMT5i																			H441														
SRP320300	SRX10918605	SRR14575435	9606	H441_PRMT5i_3	3																				Cancer cell line		PRMT5i																			H441														
SRP323714	SRX11118933	SRR14785630	9606	ADA PRMT5 Rep1																48Y					HCT116 CCL-247_ADA PRMT5		ADA treatment		MTAP-/-																	HCT116	Colorectal													
SRP323714	SRX11118934	SRR14785631	9606	ADA PRMT5 Rep2																48Y					HCT116 CCL-247_ADA PRMT5		ADA treatment		MTAP-/-																	HCT116	Colorectal													
SRP323714	SRX11118935	SRR14785632	9606	ADA PRMT5 Rep3																48Y					HCT116 CCL-247_ADA PRMT5		ADA treatment		MTAP-/-																	HCT116	Colorectal													
SRP323714	SRX11118936	SRR14785633	9606	WT PRMT5 Rep1																48Y					HCT116 CCL-247_WT PRMT5		WT		MTAP-/-																	HCT116	Colorectal													
SRP323714	SRX11118937	SRR14785634	9606	WT PRMT5 Rep2																48Y					HCT116 CCL-247_WT PRMT5		WT		MTAP-/-																	HCT116	Colorectal													
SRP323714	SRX11118938	SRR14785635	9606	WT PRMT5 Rep3																48Y					HCT116 CCL-247_WT PRMT5		WT		MTAP-/-																	HCT116	Colorectal													
SRP324755	SRX11185462	SRR14867935	9606	NCI-H460 cells, GFPkd1																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against GFP		control																	NCI-H460														
SRP324755	SRX11185463	SRR14867936	9606	NCI-H460 cells, GFPkd2																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against GFP		control																	NCI-H460														
SRP324755	SRX11185464	SRR14867937	9606	NCI-H460 cells, GFPkd3																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against GFP		control																	NCI-H460														
SRP324755	SRX11185465	SRR14867938	9606	NCI-H460 cells, PRMT5kd1																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against PRMT5		PRMT5 knockdown																	NCI-H460														
SRP324755	SRX11185466	SRR14867939	9606	NCI-H460 cells, PRMT5kd2																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against PRMT5		PRMT5 knockdown																	NCI-H460														
SRP324755	SRX11185467	SRR14867940	9606	NCI-H460 cells, PRMT5kd3																					Human lung adenocarcinoma cell line		lentivirus infection NCI-H460 for shRNA against PRMT5		PRMT5 knockdown																	NCI-H460														
SRP324902	SRX11189848	SRR14872397	9606	CHLA_20_DMSO_rep1																					CHLA-20 cells treated with DMSO replicate 1		DMSO																			CHLA-20														
SRP324902	SRX11189849	SRR14872398	9606	CHLA_20_DMSO_rep2																					CHLA-20 cells treated with DMSO replicate 2		DMSO																			CHLA-20														
SRP324902	SRX11189850	SRR14872399	9606	CHLA_20_JSK591_rep1																					CHLA-20 cells treated with JSK591 replicate 1		JSK591																			CHLA-20														
SRP324902	SRX11189851	SRR14872400	9606	CHLA_20_JSK591_rep2																					CHLA-20 cells treated with JSK591 replicate 2		JSK591																			CHLA-20														
SRP324902	SRX11189852	SRR14872401	9606	NGP_DMSO_rep1																					NGP cells treated with DMSO replicate 1		DMSO																			NGP														
SRP324902	SRX11189853	SRR14872402	9606	NGP_DMSO_rep2																					NGP cells treated with DMSO replicate 2		DMSO																			NGP														
SRP324902	SRX11189854	SRR14872403	9606	NGP_JSK591_rep1																					NGP cells treated with JSK591 replicate 1		JSK591																			NGP														
SRP324902	SRX11189855	SRR14872404	9606	NGP_JSK591_rep2																					NGP cells treated with JSK591 replicate 2		JSK591																			NGP														
SRP341597	SRX12633121	SRR16355590	9606	T24-NC																					bladder cancer cell line T24		Negative control																			bladder cancer cell line T24														
SRP341597	SRX12633122	SRR16355591	9606	T24-S1																					bladder cancer cell line T24		0.04 OD Si-RNA-1																			bladder cancer cell line T24														
SRP341597	SRX12633123	SRR16355592	9606	T24-S2																					bladder cancer cell line T24		0.04 OD Si-RNA-2																			bladder cancer cell line T24														
SRP064144	SRX1283460		9606	RNAPII ChIP, shGFP 8wg16								Expressing shRNA targeting GFP under CMV promoter.													Raji (lymphocyte)																									RNAPII CTD (8wg16) (purified in the lab)								Raji (EBNA 1 positive)		
SRP064144	SRX1283461		9606	RNAPII ChIP, shSMN 8wg16								Expressing shRNA targeting SMN under CMV promoter.													Raji (lymphocyte)																									RNAPII CTD (8wg16) (purified in the lab)								Raji (EBNA 1 positive)		
SRP064144	SRX1283462		9606	RNAPII ChIP, shGFP 4h8								Expressing shRNA targeting GFP under CMV promoter.													Raji (lymphocyte)																									RNAPII CTD, phospho-S5 (4h8) (Abcam mAb Cat # ab5408)								Raji (EBNA 1 positive)		
SRP064144	SRX1283463		9606	RNAPII ChIP, shSMN 4h8								Expressing shRNA targeting SMN under CMV promoter.													Raji (lymphocyte)																									RNAPII CTD, phospho-S5 (4h8) (Abcam mAb Cat # ab5408)								Raji (EBNA 1 positive)		
SRP064144	SRX1283464		9606	RNAPII ChIP, Wild-type RNAPII								Expressing amanitin-resistant wt POLR2A													Raji (lymphocyte)																									RNAPII (N20) (Santa Cruz pAb Cat # sc-899)								Raji (EBNA 1 positive)		
SRP064144	SRX1283465		9606	RNAPII ChIP, R1810A mutant RNAPII								Expressing amanitin-resistant R1810A mutant POLR2A													Raji (lymphocyte)																									RNAPII (N20) (Santa Cruz pAb Cat # sc-899)								Raji (EBNA 1 positive)		
SRP064144	SRX1283466		9606	SMN ChIP								Expressing Dox inducible GFP-SMN fusion protein. Construct is hygromycin resistant.													HEK293																									SMN (Santa Cruz pAb Cat # H-195)								HEK293		
SRP064144	SRX1283467		9606	SMN-GFP ChIP								Expressing Dox inducible GFP-SMN fusion protein. Construct is hygromycin resistant.													HEK293																									GFP (Abcam pAb Cat# 290)								HEK293		
SRP064144	SRX1283468		9606	IgG ChIP								Wild type													Raji (lymphocyte)																									IgG (Invitrogen Cat # 10500C)								Raji (EBNA 1 positive)		
SRP064740	SRX1331406	SRR2636948	9606	Flag-ZNF224																					HEK293 cell line transfected with Flag-ZNF224, Flag ChIP										anti-Flag M2											HEK293										Flag-ZNF224				
SRP341597	SRX13852141	SRR17688881	9606	UM-UC-3-NC																					bladder cancer cell line UM-UC-3		Negative control																			bladder cancer cell line UM-UC-3														
SRP341597	SRX13852142	SRR17688882	9606	UM-UC-3-S1																					bladder cancer cell line UM-UC-3		0.04 OD Si-RNA-1																			bladder cancer cell line UM-UC-3														
SRP341597	SRX13852143	SRR17688883	9606	UM-UC-3-S2																					bladder cancer cell line UM-UC-3		0.04 OD Si-RNA-2																			bladder cancer cell line UM-UC-3														
SRP356653	SRX13898240	SRR17735685	9606	Z-138_MIGR1_Control_rep1																					Z-138 cells		Treated with DMSO for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898241	SRR17735684	9606	Z-138_MIGR1_Control_rep2																					Z-138 cells		Treated with DMSO for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898242	SRR17735683	9606	Z-138_MIGR1_Control_rep3																					Z-138 cells		Treated with DMSO for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898243	SRR17735682	9606	Z-138_MIGR1_GSK591_rep1																					Z-138 cells		Treated with 5µM GSK591 for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898244	SRR17735681	9606	Z-138_MIGR1_GSK591_rep2																					Z-138 cells		Treated with 5µM GSK591 for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898245	SRR17735680	9606	Z-138_MIGR1_GSK591_rep3																					Z-138 cells		Treated with 5µM GSK591 for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898246	SRR17735679	9606	Z-138_MIGR1_Ro_rep1																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898247	SRR17735678	9606	Z-138_MIGR1_Ro_rep2																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898248	SRR17735677	9606	Z-138_MIGR1_Ro_rep3																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898249	SRR17735676	9606	Z-138_MIGR1_GSK591_Ro_rep1																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898250	SRR17735675	9606	Z-138_MIGR1_GSK591_Ro_rep2																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356653	SRX13898251	SRR17735674	9606	Z-138_MIGR1_GSK591_Ro_rep3																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing empty vector														48hr after retrovirus transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898301	SRR17735744	9606	Z-138_MSI2ADAR_Control_rep1																					Z-138 cells		Treated with DMSO for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898302	SRR17735743	9606	Z-138_MSI2ADAR_Control_rep2																					Z-138 cells		Treated with DMSO for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898303	SRR17735742	9606	Z-138_MSI2ADAR_Ro_rep1																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898304	SRR17735741	9606	Z-138_MSI2ADAR_Ro_rep2																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898305	SRR17735740	9606	Z-138_MSI2ADAR_Ro_rep3																					Z-138 cells		Treated with 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898306	SRR17735739	9606	Z-138_MSI2ADAR_GSK591_rep1																					Z-138 cells		Treated with 5µM GSK591 for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898307	SRR17735738	9606	Z-138_MSI2ADAR_GSK591_rep2																					Z-138 cells		Treated with 5µM GSK591 for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898308	SRR17735737	9606	Z-138_MSI2ADAR_GSK591_Ro_rep1																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898309	SRR17735736	9606	Z-138_MSI2ADAR_GSK591_Ro_rep2																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP356658	SRX13898310	SRR17735735	9606	Z-138_MSI2ADAR_GSK591_Ro_rep3																					Z-138 cells		Treated with 5µM GSK591 and 5µM Ro for 24hr				Overexpressing MSI2-HyperADAR fusion														48hr after transduction	Z-138 cells												Mantle cell lymphoma cell line		
SRP066444	SRX1439594	SRR2932154	9606	PRMT5/Knockdown_1																					AML cell line (MV4-11)_PMRT5/Knockdown																					MV4-11														
SRP066444	SRX1439595	SRR2932155	9606	PRMT5/Knockdown_2																					AML cell line (MV4-11)_PMRT5/Knockdown																					MV4-11														
SRP066444	SRX1439596	SRR2932156	9606	PRMT5/Knockdown_3																					AML cell line (MV4-11)_PMRT5/Knockdown																					MV4-11														
SRP066444	SRX1439597	SRR2932157	9606	Scrambled control_1																					AML cell line (MV4-11)_scrambled																					MV4-11														
SRP066444	SRX1439598	SRR2932158	9606	Scrambled control_2																					AML cell line (MV4-11)_scrambled																					MV4-11														
SRP066444	SRX1439599	SRR2932159	9606	Scrambled control_3																					AML cell line (MV4-11)_scrambled																					MV4-11														
SRP067045	SRX1466273	SRR2976843	9606	Input_ChIP-seq																					Input		no treatment								none (input)											breast cancer cell line MDA-MB-231														
SRP067045	SRX1466274	SRR2976844	9606	PRMT5_ChIP-seq																					PRMT5		no treatment								PRMT5 (Bethyl Labs A300-849A)											breast cancer cell line MDA-MB-231														
SRP067026	SRX1466532	SRR2977058	9606	Scrambled control shRNA_1		Scrambled control shRNA_1																			Scrambled control shRNA (control for WDR77 shRNA)		Infected cells were selected with puromycin (1mg/mL) for 5 days																			breast cancer cell line MDA-MB-231														
SRP067026	SRX1466533	SRR2977059	9606	Scrambled control shRNA_2		Scrambled control shRNA_2																			Scrambled control shRNA (control for PRMT5 shRNA)		Infected cells were selected with puromycin (1mg/mL) for 5 days																			breast cancer cell line MDA-MB-231														
SRP067026	SRX1466534	SRR2977060	9606	WDR77 shRNA		WDR77 shRNA																			WDR77 shRNA		Infected cells were selected with puromycin (1mg/mL) for 5 days																			breast cancer cell line MDA-MB-231														
SRP067026	SRX1466535	SRR2977061	9606	PRMT5 shRNA		PRMT5 shRNA																			PRMT5 shRNA		Infected cells were selected with puromycin (1mg/mL) for 5 days																			breast cancer cell line MDA-MB-231														
SRP067025	SRX1466537	SRR2977062	9606	DMSO-treated																					MDA-MB-231		5µM DMSO for 4 hours at 37°C																			breast cancer cell line MDA-MB-231														
SRP067025	SRX1466538	SRR2977063	9606	HPTB-treated																					MDA-MB-231		5µM HPTB for 4 hours at 37°C																			breast cancer cell line MDA-MB-231														
SRP379185	SRX15637843		9606	L33_Richter's_Lymph_Node_GEX													SI-TT-B1								Lymph Node	Richter's Transformation		Lymph Node																																
SRP379185	SRX15637844		9606	L34_Richter's_PBMC_GEX													SI-TT-C2								PBMC	Richter's Transformation		PBMC																																
SRP379185	SRX15637845		9606	L35_CLL_PBMC_GEX													SI-TT-D3								PBMC	Chronic Lymphocytic Leukemia		PBMC																																
SRP379185	SRX15637846		9606	L36_Richter's_Lymph_Node_GEX													SI-TT-E4								Lymph Node	Richter's Transformation		Lymph Node																																
SRP379185	SRX15637847		9606	L37_Richter's_PBMC_GEX													SI-TT-F5								PBMC	Richter's Transformation		PBMC																																
SRP379185	SRX15637848		9606	L38_CLL_PBMC_GEX													SI-TT-G6								PBMC	Chronic Lymphocytic Leukemia		PBMC																																
SRP379185	SRX15637849		9606	L33_Richter's_Lymph_Node_VDJ													SI-TT-A1								Lymph Node	Richter's Transformation		Lymph Node																																
SRP379185	SRX15637850		9606	L34_Richter's_PBMC_VDJ													SI-TT-B2								PBMC	Richter's Transformation		PBMC																																
SRP379185	SRX15637851		9606	L35_CLL_PBMC_VDJ													SI-TT-C3								PBMC	Chronic Lymphocytic Leukemia		PBMC																																
SRP379185	SRX15637852		9606	L36_Richter's_Lymph_Node_VDJ													SI-TT-D4								Lymph Node	Richter's Transformation		Lymph Node																																
SRP379185	SRX15637853		9606	L37_Richter's_PBMC_VDJ													SI-TT-E5								PBMC	Richter's Transformation		PBMC																																
SRP379185	SRX15637854		9606	L38_CLL_PBMC_VDJ													SI-TT-F6								PBMC	Chronic Lymphocytic Leukemia		PBMC																																
SRP379612	SRX15675477	SRR19624864	9606	hEnSC,Control,1																					Endometrium			Endometrium								0h		8-Br-cAMP,MPA										solvent										stromal cells		
SRP379612	SRX15675478	SRR19624863	9606	hEnSC,Control,2																					Endometrium			Endometrium								0h		8-Br-cAMP,MPA										solvent										stromal cells		
SRP379612	SRX15675479	SRR19624862	9606	hEnSC,Control,Decidual1																					Endometrium			Endometrium								48h		8-Br-cAMP,MPA										solvent										stromal cells		
SRP379612	SRX15675480	SRR19624861	9606	hEnSC,Control,Decidual2																					Endometrium			Endometrium								48h		8-Br-cAMP,MPA										solvent										stromal cells		
SRP379612	SRX15675481	SRR19624860	9606	hEnSC,GSK591,1																					Endometrium			Endometrium								0h		8-Br-cAMP,MPA										GSK591										stromal cells		
SRP379612	SRX15675482	SRR19624859	9606	hEnSC,GSK591,2																					Endometrium			Endometrium								0h		8-Br-cAMP,MPA										GSK591										stromal cells		
SRP379612	SRX15675483	SRR19624858	9606	hEnSC,GSK591,Decidual1																					Endometrium			Endometrium								48h		8-Br-cAMP,MPA										GSK591										stromal cells		
SRP379612	SRX15675484	SRR19624857	9606	hEnSC,GSK591,Decidual2																					Endometrium			Endometrium								48h		8-Br-cAMP,MPA										GSK591										stromal cells		
SRP071668	SRX1629239	SRR3222464	9606	sh2 R1881 1 AR																					cell line VCaP		R1881								AR					PRMT5 sh2						VCaP														
SRP071668	SRX1629240	SRR3222465	9606	NTC R1881 2 AR																					cell line VCaP		R1881								AR					PRMT5 NTC						VCaP														
SRP071668	SRX1629241	SRR3222466	9606	sh1 R1881 2 AR																					cell line VCaP		R1881								AR					PRMT5 sh1						VCaP														
SRP071668	SRX1629242	SRR3222467	9606	sh2 R1881 2 AR																					cell line VCaP		R1881								AR					PRMT5 sh2						VCaP														
SRP071668	SRX1629243	SRR3222468	9606	NTC DHT 2 AR																					cell line VCaP		DHT								AR					PRMT5 NTC						VCaP														
SRP071668	SRX1629244	SRR3222469	9606	sh1 DHT 2 AR																					cell line VCaP		DHT								AR					PRMT5 sh1						VCaP														
SRP071668	SRX1629245	SRR3222470	9606	sh2 DHT 2 AR																					cell line VCaP		DHT								AR					PRMT5 sh2						VCaP														
SRP071668	SRX1629246	SRR3222471	9606	sh3 DHT 2 AR																					cell line VCaP		DHT								AR					PRMT5 sh3						VCaP														
SRP071668	SRX1629247	SRR3222472	9606	NTC DHT 3 AR																					cell line VCaP		DHT								AR					PRMT5 NTC						VCaP														
SRP071668	SRX1629248	SRR3222473	9606	sh1 DHT 3 AR																					cell line VCaP		DHT								AR					PRMT5 sh1						VCaP														
SRP071668	SRX1629249	SRR3222474	9606	sh2 DHT 3 AR																					cell line VCaP		DHT								AR					PRMT5 sh2						VCaP														
SRP071668	SRX1629250	SRR3222475	9606	sh3 DHT 3 AR																					cell line VCaP		DHT								AR					PRMT5 sh3						VCaP														
SRP071668	SRX1629251	SRR3222476	9606	NTC DHT 1 ERG																					cell line VCaP		DHT								ERG					PRMT5 NTC						VCaP														
SRP071668	SRX1629252	SRR3222477	9606	sh1 DHT 1 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh1						VCaP														
SRP071668	SRX1629253	SRR3222478	9606	sh2 DHT 1 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh2						VCaP														
SRP071668	SRX1629254	SRR3222479	9606	sh3 DHT 1 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh3						VCaP														
SRP071668	SRX1629255	SRR3222480	9606	NTC DHT 2 ERG																					cell line VCaP		DHT								ERG					PRMT5 NTC						VCaP														
SRP071668	SRX1629256	SRR3222481	9606	sh1 DHT 2 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh1						VCaP														
SRP071668	SRX1629257	SRR3222482	9606	sh2 DHT 2 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh2						VCaP														
SRP071668	SRX1629258	SRR3222483	9606	sh3 DHT 2 ERG																					cell line VCaP		DHT								ERG					PRMT5 sh3						VCaP														
SRP388148	SRX16671701	SRR20648579	9606	CHL1 cell, CDK4/6 inhibition,6 days, 2																					CHL1		CDK4/6 inhibition		WT																6 days	CHL1												melanoma cell		
SRP388148	SRX16671702	SRR20648578	9606	CHL1 cell, CDK4/6 inhibition,6 days, 1																					CHL1		CDK4/6 inhibition		WT																6 days	CHL1												melanoma cell		
SRP388148	SRX16671703	SRR20648577	9606	CHL1 cell, PRMT5 inhibition,72 hours, 2																					CHL1		PRMT5 inhibition		WT																72 hours	CHL1												melanoma cell		
SRP388148	SRX16671704	SRR20648576	9606	CHL1 cell, PRMT5 inhibition,72 hours, 1																					CHL1		PRMT5 inhibition		WT																72 hours	CHL1												melanoma cell		
SRP388148	SRX16671705	SRR20648575	9606	CHL1 cell, CDK4/6 inhibition,72 hours, 2																					CHL1		CDK4/6 inhibition		WT																72 hours	CHL1												melanoma cell		
SRP388148	SRX16671706	SRR20648574	9606	CHL1 cell, CDK4/6 inhibition,72 hours, 1																					CHL1		CDK4/6 inhibition		WT																72 hours	CHL1												melanoma cell		
SRP388148	SRX16671707	SRR20648573	9606	CHL1 cell, control,72 hours, 2																					CHL1		Control		WT																72 hours	CHL1												melanoma cell		
SRP388148	SRX16671708	SRR20648572	9606	CHL1 cell, control,72 hours, 1																					CHL1		Control		WT																72 hours	CHL1												melanoma cell		
SRP073189	SRX1693951	SRR3362661	9606	A549_GFPkd_1															GFP (control knockdown)						A549 lung adenocarcinoma control (GFP) knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693952	SRR3362662	9606	A549_GFPkd_2															GFP (control knockdown)						A549 lung adenocarcinoma control (GFP) knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693953	SRR3362663	9606	A549_GFPkd_3															GFP (control knockdown)						A549 lung adenocarcinoma control (GFP) knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693954	SRR3362664	9606	A549_PRMT5kd_1															PRMT5 knockdown						A549 lung adenocarcinoma PRMT5 shRNA knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693955	SRR3362665	9606	A549_PRMT5kd_2															PRMT5 knockdown						A549 lung adenocarcinoma PRMT5 shRNA knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693956	SRR3362666	9606	A549_PRMT5kd_3															PRMT5 knockdown						A549 lung adenocarcinoma PRMT5 shRNA knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693957	SRR3362667	9606	A549_MEP50kd_1															MEP50 knockdown						A549 lung adenocarcinoma MEP50 shRNA knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693958	SRR3362668	9606	A549_MEP50kd_2															MEP50 knockdown						A549 lung adenocarcinoma MEP50 shRNA knockdown																					A549 lung adenocarcinoma														
SRP073189	SRX1693959	SRR3362669	9606	A549_MEP50kd_3															MEP50 knockdown						A549 lung adenocarcinoma MEP50 shRNA knockdown																					A549 lung adenocarcinoma														
SRP388148	SRX19630386	SRR23798296	9606	A375 cell, control,6 days [SA-SPLICE19-1_S1]																					SA-SPLICE19-1_S1		Control	SA-SPLICE19-1_S1	WT																	A375												melanoma cell		
SRP388148	SRX19630387	SRR23798295	9606	A375 cell, control,6 days [SA-SPLICE19-2_S2]																					SA-SPLICE19-2_S2		Control	SA-SPLICE19-2_S2	WT																	A375												melanoma cell		
SRP388148	SRX19630388	SRR23798294	9606	A375 cell, CDK4/6 inhibition,6 days [SA-SPLICE19-3_S3]																					SA-SPLICE19-3_S3		CDK4/6 inhibition	SA-SPLICE19-3_S3	WT																	A375												melanoma cell		
SRP388148	SRX19630389	SRR23798293	9606	A375 cell, CDK4/6 inhibition,6 days [SA-SPLICE19-4_S4]																					SA-SPLICE19-4_S4		CDK4/6 inhibition	SA-SPLICE19-4_S4	WT																	A375												melanoma cell		
SRP097000	SRX2501925	SRR5185918	9606	DMSO replicate 1																					U-87 MG cells, DMSO		DMSO															10 ul per 10 ml media				U-87 MG							72h							
SRP097000	SRX2501926	SRR5185919	9606	DMSO replicate 2																					U-87 MG cells, DMSO		DMSO															10 ul per 10 ml media				U-87 MG							72h							
SRP097000	SRX2501927	SRR5185920	9606	DMSO replicate 3																					U-87 MG cells, DMSO		DMSO															10 ul per 10 ml media				U-87 MG							72h							
SRP097000	SRX2501928	SRR5185921	9606	EPZ015666 replicate 1																					U-87 MG cells, EPZ015666		EPZ015666															10 uM				U-87 MG							72h							
SRP097000	SRX2501929	SRR5185922	9606	EPZ015666 replicate 2																					U-87 MG cells, EPZ015666		EPZ015666															10 uM				U-87 MG							72h							
SRP097000	SRX2501930	SRR5185923	9606	EPZ015666 replicate 3																					U-87 MG cells, EPZ015666		EPZ015666															10 uM				U-87 MG							72h							
SRP126247	SRX3450460	SRR6353795	9606	MCF7-shCTRL Rep1								shCTRL											MCF7		MCF7 shCTRL ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP126247	SRX3450461	SRR6353796	9606	MCF7-shCTRL Rep2								shCTRL											MCF7		MCF7 shCTRL ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP126247	SRX3450462	SRR6353797	9606	MCF7-shCTRL Rep3								shCTRL											MCF7		MCF7 shCTRL ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP126247	SRX3450463	SRR6353798	9606	MCF7-shPRMT5 Rep1								shPRMT5											MCF7		MCF7 shPRMT5 ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP126247	SRX3450464	SRR6353799	9606	MCF7-shPRMT5 Rep2								shPRMT5											MCF7		MCF7 shPRMT5 ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP126247	SRX3450465	SRR6353800	9606	MCF7-shPRMT5 Rep3								shPRMT5											MCF7		MCF7 shPRMT5 ESA+CD24lowCD44+ cells																																	ESA+CD24lowCD44+ cells		
SRP127787	SRX3524974		9606	MAVER1_day3_vehicle																					CellLine: MAVER-1							Mantle Cell Lymphoma									Vehicle				Day 3	MAVER-1														
SRP127787	SRX3524975		9606	MAVER1_day3_200nM_GSK595																					CellLine: MAVER-1							Mantle Cell Lymphoma									200nM GSK3326595				Day 3	MAVER-1														
SRP127787	SRX3524976		9606	MAVER1_day6_vehicle																					CellLine: MAVER-1							Mantle Cell Lymphoma									Vehicle				Day 6	MAVER-1														
SRP127787	SRX3524977		9606	MAVER1_day6_200nM_GSK595																					CellLine: MAVER-1							Mantle Cell Lymphoma									200nM GSK3326595				Day 6	MAVER-1														
SRP127787	SRX3524978		9606	JVM2_day3_vehicle																					CellLine: JVM-2							Mantle Cell Lymphoma									Vehicle				Day 3	JVM-2														
SRP127787	SRX3524979		9606	JVM2_day3_200nM_GSK595																					CellLine: JVM-2							Mantle Cell Lymphoma									200nM GSK3326595				Day 3	JVM-2														
SRP127787	SRX3524980		9606	JVM2_day6_vehicle																					CellLine: JVM-2							Mantle Cell Lymphoma									Vehicle				Day 6	JVM-2														
SRP127787	SRX3524981		9606	JVM2_day6_200nM_GSK595																					CellLine: JVM-2							Mantle Cell Lymphoma									200nM GSK3326595				Day 6	JVM-2														
SRP127787	SRX3524982		9606	SUDHL6_day3_vehicle																					CellLine: SU-DHL-6							Diffuse Large B-cell Lymphoma									Vehicle				Day 3	SU-DHL-6														
SRP127787	SRX3524983		9606	SUDHL6_day3_200nM_GSK595																					CellLine: SU-DHL-6							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 3	SU-DHL-6														
SRP127787	SRX3524984		9606	SUDHL6_day6_vehicle																					CellLine: SU-DHL-6							Diffuse Large B-cell Lymphoma									Vehicle				Day 6	SU-DHL-6														
SRP127787	SRX3524985		9606	SUDHL6_day6_200nM_GSK595																					CellLine: SU-DHL-6							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 6	SU-DHL-6														
SRP127787	SRX3524986		9606	SUDHL5_day3_vehicle																					CellLine: SU-DHL-5							Diffuse Large B-cell Lymphoma									Vehicle				Day 3	SU-DHL-5														
SRP127787	SRX3524987		9606	SUDHL5_day3_200nM_GSK595																					CellLine: SU-DHL-5							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 3	SU-DHL-5														
SRP127787	SRX3524988		9606	SUDHL5_day6_vehicle																					CellLine: SU-DHL-5							Diffuse Large B-cell Lymphoma									Vehicle				Day 6	SU-DHL-5														
SRP127787	SRX3524989		9606	SUDHL5_day6_200nM_GSK595																					CellLine: SU-DHL-5							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 6	SU-DHL-5														
SRP127787	SRX3524990		9606	SUDHL4_day3_vehicle																					CellLine: SU-DHL-4							Diffuse Large B-cell Lymphoma									Vehicle				Day 3	SU-DHL-4														
SRP127787	SRX3524991		9606	SUDHL4_day3_200nM_GSK595																					CellLine: SU-DHL-4							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 3	SU-DHL-4														
SRP127787	SRX3524992		9606	SUDHL4_day6_vehicle																					CellLine: SU-DHL-4							Diffuse Large B-cell Lymphoma									Vehicle				Day 6	SU-DHL-4														
SRP127787	SRX3524993		9606	SUDHL4_day6_200nM_GSK595																					CellLine: SU-DHL-4							Diffuse Large B-cell Lymphoma									200nM GSK3326595				Day 6	SU-DHL-4														
SRP134236	SRX3777460	SRR6820615	9606	IR- Dox- 1								No knockdown		0 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777461	SRR6820616	9606	IR- Dox+ 1								PRMT5 knockdown		0 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP134236	SRX3777462	SRR6820617	9606	IR- Dox- 2								No knockdown		0 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777463	SRR6820618	9606	IR- Dox+ 2								PRMT5 knockdown		0 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP134236	SRX3777464	SRR6820619	9606	IR- Dox- 3								No knockdown		0 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777465	SRR6820620	9606	IR- Dox+ 3								PRMT5 knockdown		0 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP134236	SRX3777466	SRR6820621	9606	IR+ Dox- 1R								No knockdown		2 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777467	SRR6820622	9606	IR+ Dox+ 1R								PRMT5 knockdown		2 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP134236	SRX3777468	SRR6820623	9606	IR+ Dox- 2R								No knockdown		2 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777469	SRR6820624	9606	IR+ Dox+ 2R								PRMT5 knockdown		2 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP134236	SRX3777470	SRR6820625	9606	IR+ Dox- 3R								No knockdown		2 Gy radiation											Prostate cancer		Dox-																			LNCaP-shPRMT5														
SRP134236	SRX3777471	SRR6820626	9606	IR+ Dox+ 3R								PRMT5 knockdown		2 Gy radiation											Prostate cancer		Dox+																			LNCaP-shPRMT5														
SRP135890	SRX3803252	SRR6847870	9606	NT siRNA E2F-1 RIP-seq 1																					U2OS cells																					U2OS									25nM NT siRNA, 72h			Osteosarcoma, epithelial		
SRP135890	SRX3803253	SRR6847871	9606	NT siRNA E2F-1 RIP-seq 2																					U2OS cells																					U2OS									25nM NT siRNA, 72h			Osteosarcoma, epithelial		
SRP135890	SRX3803254	SRR6847872	9606	TSN siRNA E2F-1 RIP-seq 1																					U2OS cells																					U2OS									25nM p100/TSN siRNA, 72h			Osteosarcoma, epithelial		
SRP135890	SRX3803255	SRR6847873	9606	TSN siRNA E2F-1 RIP-seq 2																					U2OS cells																					U2OS									25nM p100/TSN siRNA, 72h			Osteosarcoma, epithelial		
SRP135890	SRX3803256	SRR6847874	9606	E2F-1 siRNA E2F-1 RIP-seq																					U2OS cells																					U2OS									25nM E2F-1 siRNA, 72h			Osteosarcoma, epithelial		
SRP135891	SRX3803257	SRR6847875	9606	pTRE cell line RNA-seq replicate 1																					pTRE U2OS stable cells												empty vector cell line									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803258	SRR6847876	9606	pTRE cell line RNA-seq replicate 2																					pTRE U2OS stable cells												empty vector cell line									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803259	SRR6847877	9606	pTRE cell line RNA-seq replicate 3																					pTRE U2OS stable cells												empty vector cell line									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803260	SRR6847878	9606	WT cell line RNA-seq replicate 1																					WT U2OS stable cells												HA-tagged wild-type E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803261	SRR6847879	9606	WT cell line RNA-seq replicate 2																					WT U2OS stable cells												HA-tagged wild-type E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803262	SRR6847880	9606	WT cell line RNA-seq replicate 3																					WT U2OS stable cells												HA-tagged wild-type E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803263	SRR6847881	9606	R109K cell line RNA-seq replicate 1																					R109K U2OS stable cells												HA-tagged R109K mutated E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803264	SRR6847882	9606	R109K cell line RNA-seq replicate 2																					R109K U2OS stable cells												HA-tagged R109K mutated E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803265	SRR6847883	9606	R109K cell line RNA-seq replicate 3																					R109K U2OS stable cells												HA-tagged R109K mutated E2F-1									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803266	SRR6847884	9606	KK cell line RNA-seq replicate 1																					KK U2OS stable cells												HA-tagged R111/113K mutated E2F-1 (KK)									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803267	SRR6847885	9606	KK cell line RNA-seq replicate 2																					KK U2OS stable cells												HA-tagged R111/113K mutated E2F-1 (KK)									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP135891	SRX3803268	SRR6847886	9606	KK cell line RNA-seq replicate 3																					KK U2OS stable cells												HA-tagged R111/113K mutated E2F-1 (KK)									U2OS									1ug/ml doxycycline, 24h			Osteosarcoma, epithelial		
SRP149386	SRX4145141	SRR7239310	9606	TMD8 sgPRMT5 0-1								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 0 day																20ng/ml doxycycline for 0 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145142	SRR7239311	9606	TMD8 sgPRMT5 0-2								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 0 day																20ng/ml doxycycline for 0 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145143	SRR7239312	9606	TMD8 sgPRMT5 3-1								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 3 days																20ng/ml doxycycline for 3 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145144	SRR7239313	9606	TMD8 sgPRMT5 3-2								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 3 days																20ng/ml doxycycline for 3 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145145	SRR7239314	9606	TMD8 sgPRMT5 6-1								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 6 days																20ng/ml doxycycline for 6 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145146	SRR7239315	9606	TMD8 sgPRMT5 6-2								expressing sgRNA targeting PRMT5													TMD8 sgPRMT5 6 days																20ng/ml doxycycline for 6 days.					TMD8												ABC DLBCL cell line		
SRP149386	SRX4145147	SRR7239316	9606	OCI-Ly7 sgPRMT5 0-1								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 0 day																20ng/ml doxycycline for 0 days.					OCI-Ly7												GCB DLBCL cell line		
SRP149386	SRX4145148	SRR7239317	9606	OCI-Ly7 sgPRMT5 0-2								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 0 day																20ng/ml doxycycline for 0 days.					OCI-Ly7												GCB DLBCL cell line		
SRP149386	SRX4145149	SRR7239318	9606	OCI-Ly7 sgPRMT5 3-1								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 3 days																20ng/ml doxycycline for 3 days.					OCI-Ly7												GCB DLBCL cell line		
SRP149386	SRX4145150	SRR7239319	9606	OCI-Ly7 sgPRMT5 3-2								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 3 days																20ng/ml doxycycline for 3 days.					OCI-Ly7												GCB DLBCL cell line		
SRP149386	SRX4145151	SRR7239320	9606	OCI-Ly7 sgPRMT5 6-1								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 6 days																20ng/ml doxycycline for 6 days.					OCI-Ly7												GCB DLBCL cell line		
SRP149386	SRX4145152	SRR7239321	9606	OCI-Ly7 sgPRMT5 6-2								expressing sgRNA targeting PRMT5													OCI-Ly7 sgPRMT5 6 days																20ng/ml doxycycline for 6 days.					OCI-Ly7												GCB DLBCL cell line		
SRP153104	SRX4381885	SRR7511789	9606	SUDHL6_VEH_24H_R1																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														24 h
SRP153104	SRX4381886	SRR7511790	9606	SUDHL6_VEH_24H_R2																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														24 h
SRP153104	SRX4381887	SRR7511791	9606	SUDHL6_VEH_24H_R3																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														24 h
SRP153104	SRX4381888	SRR7511792	9606	SUDHL6_GSK591_24H_R1																					SUDHL6 cells		200nm GSK591																			SUDHL6														24 h
SRP153104	SRX4381889	SRR7511793	9606	SUDHL6_GSK591_24H_R2																					SUDHL6 cells		200nm GSK591																			SUDHL6														24 h
SRP153104	SRX4381890	SRR7511794	9606	SUDHL6_GSK591_24H_R3																					SUDHL6 cells		200nm GSK591																			SUDHL6														24 h
SRP153104	SRX4381891	SRR7511795	9606	SUDHL6_VEH_96H_R1																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														96 h
SRP153104	SRX4381892	SRR7511796	9606	SUDHL6_VEH_96H_R2																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														96 h
SRP153104	SRX4381893	SRR7511797	9606	SUDHL6_VEH_96H_R3																					SUDHL6 cells		Vehicle (0.01% DMSO)																			SUDHL6														96 h
SRP153104	SRX4381894	SRR7511798	9606	SUDHL6_GSK591_96H_R1																					SUDHL6 cells		200nm GSK591																			SUDHL6														96 h
SRP153104	SRX4381895	SRR7511799	9606	SUDHL6_GSK591_96H_R2																					SUDHL6 cells		200nm GSK591																			SUDHL6														96 h
SRP153104	SRX4381896	SRR7511800	9606	SUDHL6_GSK591_96H_R3																					SUDHL6 cells		200nm GSK591																			SUDHL6														96 h
SRP149386	SRX4923686	SRR8096863	12111				Illumina Nextera XT	Bos taurus	Passaged once in LFBK-_V_6 cells	A			3					laboratory / experimental			Experimental inocculum was A24/Cruzeiro/BoPass2 Harvested 28Dec2005, SRA accession: SRP149386												non-vaccinated bovine 14-34	not applicable									Saliva						Viral		not applicable									
SRP186070	SRX5383617	SRR8582918	9606	PANC08.13_N1_DMSO	Replicate #1																				Pancreatic cancer cell line		Control (DMSO)																			PANC08.13														
SRP186070	SRX5383618	SRR8582919	9606	PANC08.13_N1_GSK712	Replicate #1																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC08.13														
SRP186070	SRX5383619	SRR8582920	9606	PANC08.13_N2_DMSO	Replicate #2																				Pancreatic cancer cell line		Control (DMSO)																			PANC08.13														
SRP186070	SRX5383620	SRR8582921	9606	PANC08.13_N2_GSK712	Replicate #2																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC08.13														
SRP186070	SRX5383621	SRR8582922	9606	PANC03.27_MTAP_WT_DMSO_N1	Replicate #1																				Pancreatic cancer cell line		Control (DMSO)																			PANC03.27						Parental								
SRP186070	SRX5383622	SRR8582923	9606	PANC03.27_MTAP_WT_DMSO_N2	Replicate #2																				Pancreatic cancer cell line		Control (DMSO)																			PANC03.27						Parental								
SRP186070	SRX5383623	SRR8582924	9606	PANC03.27_MTAP_WT_GSK712_N1	Replicate #1																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC03.27						Parental								
SRP186070	SRX5383624	SRR8582925	9606	PANC03.27_MTAP_WT_GSK712_N2	Replicate #2																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC03.27						Parental								
SRP186070	SRX5383625	SRR8582926	9606	PANC03.27_MTAP_WT_GSK591_N1	Replicate #1																				Pancreatic cancer cell line		Treated (GSK3203591)																			PANC03.27						Parental								
SRP186070	SRX5383626	SRR8582927	9606	PANC03.27_MTAP_WT_GSK591_N2	Replicate #2																				Pancreatic cancer cell line		Treated (GSK3203591)																			PANC03.27						Parental								
SRP186070	SRX5383627	SRR8582928	9606	PANC03.27_MTAP_WT_Combo_N1	Replicate #1																				Pancreatic cancer cell line		Treated (Combination)																			PANC03.27						Parental								
SRP186070	SRX5383628	SRR8582929	9606	PANC03.27_MTAP_WT_Combo_N2	Replicate #2																				Pancreatic cancer cell line		Treated (Combination)																			PANC03.27						Parental								
SRP186070	SRX5383629	SRR8582930	9606	PANC03.27_MTAP_KO_DMSO_N1	Replicate #1																				Pancreatic cancer cell line		Control (DMSO)																			PANC03.27						Knock out								
SRP186070	SRX5383630	SRR8582931	9606	PANC03.27_MTAP_KO_DMSO_N2	Replicate #2																				Pancreatic cancer cell line		Control (DMSO)																			PANC03.27						Knock out								
SRP186070	SRX5383631	SRR8582932	9606	PANC03.27_MTAP_KO_GSK712_N1	Replicate #1																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC03.27						Knock out								
SRP186070	SRX5383632	SRR8582933	9606	PANC03.27_MTAP_KO_GSK712_N2	Replicate #2																				Pancreatic cancer cell line		Treated (GSK3368712)																			PANC03.27						Knock out								
SRP186070	SRX5383633	SRR8582934	9606	PANC03.27_MTAP_KO_GSK591_N1	Replicate #1																				Pancreatic cancer cell line		Treated (GSK3203591)																			PANC03.27						Knock out								
SRP186070	SRX5383634	SRR8582935	9606	PANC03.27_MTAP_KO_GSK591_N2	Replicate #2																				Pancreatic cancer cell line		Treated (GSK3203591)																			PANC03.27						Knock out								
SRP186070	SRX5383635	SRR8582936	9606	PANC03.27_MTAP_KO_Combo_N1	Replicate #1																				Pancreatic cancer cell line		Treated (Combination)																			PANC03.27						Knock out								
SRP186070	SRX5383636	SRR8582937	9606	PANC03.27_MTAP_KO_Combo_N2	Replicate #2																				Pancreatic cancer cell line		Treated (Combination)																			PANC03.27						Knock out								
SRP188498	SRX5524953	SRR8732091	9606	CB11 MLL-AF4																		CB11			CD34+ HSPCs from cord blood														t(4;11)(q21;q23)																			CD34+ HSPCs from cord blood		
SRP188498	SRX5524954	SRR8732092	9606	CB11 control																		CB11			CD34+ HSPCs from cord blood														control																			CD34+ HSPCs from cord blood		
SRP188498	SRX5524955	SRR8732093	9606	CB12 MLL-AF4																		CB12			CD34+ HSPCs from cord blood														t(4;11)(q21;q23)																			CD34+ HSPCs from cord blood		
SRP188498	SRX5524956	SRR8732094	9606	CB12 control																		CB12			CD34+ HSPCs from cord blood														control																			CD34+ HSPCs from cord blood		
SRP192029	SRX5668347		9606	THP-1 cells_sgNegCtrl																					Acute myeloid leukemia cell line			peripheral blood	control																	THP-1												monocyte	suspension	
SRP192029	SRX5668348		9606	THP-1 cells_sgPRMT5																					Acute myeloid leukemia cell line			peripheral blood	PRMT5 knockdown																	THP-1												monocyte	suspension	
SRP193479	SRX5725633	SRR8945501	9606	HeLa: input DNA																					HeLa cell										none											HeLa														
SRP193479	SRX5725634	SRR8945502	9606	HeLa: Snail_ChIPSeq																					HeLa cell										Snail											HeLa														
SRP193479	SRX5725635		9606	HeLa: MTA1_ChIPSeq																					HeLa cell										MTA1											HeLa														
SRP193479	SRX5725636		9606	HeLa: PRMT5_ChIPSeq																					HeLa cell										PRMT5											HeLa														
SRP200813	SRX5987866	SRR9217367	9606	Molm13_DMSO_rep1																					Molm13																					Molm13											DMSO Control	Acute Myeloid Leukemia		
SRP200813	SRX5987867	SRR9217368	9606	Molm13_DMSO_rep2																					Molm13																					Molm13											DMSO Control	Acute Myeloid Leukemia		
SRP200813	SRX5987868	SRR9217369	9606	Molm13_DMSO_rep3																					Molm13																					Molm13											DMSO Control	Acute Myeloid Leukemia		
SRP200813	SRX5987869	SRR9217370	9606	Molm13_DMSO_rep4																					Molm13																					Molm13											DMSO Control	Acute Myeloid Leukemia		
SRP200813	SRX5987870	SRR9217371	9606	Molm13_EZH2i_rep1																					Molm13																					Molm13											EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987871	SRR9217372	9606	Molm13_EZH2i_rep2																					Molm13																					Molm13											EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987872	SRR9217373	9606	Molm13_EZH2i_rep3																					Molm13																					Molm13											EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987873	SRR9217374	9606	Molm13_EZH2i_rep4																					Molm13																					Molm13											EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987874	SRR9217375	9606	Molm13_P5i_1uM_rep1																					Molm13																					Molm13											PRMT5 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987875	SRR9217376	9606	Molm13_P5i_1uM_rep2																					Molm13																					Molm13											PRMT5 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987876	SRR9217377	9606	Molm13_P5i_1uM_rep3																					Molm13																					Molm13											PRMT5 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987877	SRR9217378	9606	Molm13_P5i_1uM_rep4																					Molm13																					Molm13											PRMT5 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987878	SRR9217379	9606	Molm13_PE_rep1																					Molm13																					Molm13											PRMT5 and EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987879	SRR9217380	9606	Molm13_PE_rep2																					Molm13																					Molm13											PRMT5 and EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987880	SRR9217381	9606	Molm13_PE_rep3																					Molm13																					Molm13											PRMT5 and EZH2 Inhibition	Acute Myeloid Leukemia		
SRP200813	SRX5987881	SRR9217382	9606	Molm13_PE_rep4																					Molm13																					Molm13											PRMT5 and EZH2 Inhibition	Acute Myeloid Leukemia		
SRP212665	SRX6384947		9606	A375AR991-S2	Replicate 1																				A375AR991 cell line		increasing concentrations of palbociclib for 7 months																			A375AR991	Melanoma													
SRP212665	SRX6384948		9606	A375AR991-S3	Replicate 2																				A375AR991 cell line		increasing concentrations of palbociclib for 7 months																			A375AR991	Melanoma													
SRP212665	SRX6384949		9606	A375AR991-S4	Replicate 3																				A375AR991 cell line		increasing concentrations of palbociclib for 7 months																			A375AR991	Melanoma													
SRP212665	SRX6384950		9606	A375-S2	Replicate 1																				A375 cell line		No treatment																			A375	Melanoma													
SRP212665	SRX6384951		9606	A375-S3	Replicate 2																				A375 cell line		No treatment																			A375	Melanoma													
SRP212665	SRX6384952		9606	A375-S4	Replicate 3																				A375 cell line		No treatment																			A375	Melanoma													
SRP212665	SRX6384953		9606	CHL1AR991-S2	Replicate 1																				CHL1AR991 cell line		increasing concentrations of palbociclib for 3 months																			CHL1AR991	Melanoma													
SRP212665	SRX6384954		9606	CHL1AR991-S3	Replicate 2																				CHL1AR991 cell line		increasing concentrations of palbociclib for 3 months																			CHL1AR991	Melanoma													
SRP212665	SRX6384955		9606	CHL1AR991-S4	Replicate 3																				CHL1AR991 cell line		increasing concentrations of palbociclib for 3 months																			CHL1AR991	Melanoma													
SRP212665	SRX6384956		9606	CHL1-S2	Replicate 1																				CHL1 cell line		No treatment																			CHL1	Melanoma													
SRP212665	SRX6384957		9606	CHL1-S3	Replicate 2																				CHL1 cell line		No treatment																			CHL1	Melanoma													
SRP212665	SRX6384958		9606	CHL1-S4	Replicate 3																				CHL1 cell line		No treatment																			CHL1	Melanoma													
SRP212666	SRX6384959	SRR9622111	9606	A375-DMSO-72hr-1	Replicate 1																				A375-DMSO-72hr		Vehicle (DMSO) - 72 hr																			A375	Melanoma													
SRP212666	SRX6384960	SRR9622112	9606	A375-DMSO-72hr-2	Replicate 2																				A375-DMSO-72hr		Vehicle (DMSO) - 72 hr																			A375	Melanoma													
SRP212666	SRX6384961	SRR9622113	9606	A375-PD991-72hr-1	Replicate 1																				A375-PD991-72hr		Palbociclib (PD991) - 72hr																			A375	Melanoma													
SRP212666	SRX6384962	SRR9622114	9606	A375-PD991-72hr-2	Replicate 2																				A375-PD991-72hr		Palbociclib (PD991) - 72hr																			A375	Melanoma													
SRP212666	SRX6384963	SRR9622115	9606	A375-CTX-72hr-1	Replicate 1																				A375-CTX-72hr		GSK3326595 (CTX) - 72hr																			A375	Melanoma													
SRP212666	SRX6384964	SRR9622116	9606	A375-CTX-72hr-2	Replicate 2																				A375-CTX-72hr		GSK3326595 (CTX) - 72hr																			A375	Melanoma													
SRP192029	SRX6592099		9606	sgNegCtrl								control													Acute myeloid leukemia cell line			peripheral blood																		THP-1				SRSF1 antibody								monocyte	suspension	
SRP192029	SRX6592100		9606	sgPRMT5								PRMT5 knockdown													Acute myeloid leukemia cell line			peripheral blood																		THP-1				SRSF1 antibody								monocyte	suspension	
SRP235229	SRX7290481	SRR10611209	9606	72h DMSO activated CD4+ rep 2																					72h DMSO activated CD4+		72h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290482	SRR10611210	9606	72h DMSO activated CD4+ rep 3																					72h DMSO activated CD4+		72h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290483	SRR10611211	9606	72h PF-9927 activated CD4+ rep 1																					72h PF-9927 activated CD4+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290484	SRR10611212	9606	72h PF-9927 activated CD4+ rep 2																					72h PF-9927 activated CD4+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290485	SRR10611213	9606	72h PF-9927 activated CD4+ rep 3																					72h PF-9927 activated CD4+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290486	SRR10611214	9606	Naïve CD8+ rep 1																					Naïve CD8+			peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290487	SRR10611215	9606	Naïve CD8+ rep 2																					Naïve CD8+			peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290488	SRR10611216	9606	Naïve CD8+ rep 3																					Naïve CD8+			peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290489	SRR10611217	9606	72h DMSO activated CD8+ rep 1																					72h DMSO activated CD8+		72h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290490	SRR10611218	9606	72h DMSO activated CD8+ rep 2																					72h DMSO activated CD8+		72h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290491	SRR10611219	9606	72h DMSO activated CD8+ rep 3																					72h DMSO activated CD8+		72h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290492	SRR10611220	9606	72h PF-9927 activated CD8+ rep 1																					72h PF-9927 activated CD8+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290493	SRR10611221	9606	72h PF-9927 activated CD8+ rep 2																					72h PF-9927 activated CD8+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290494	SRR10611222	9606	72h PF-9927 activated CD8+ rep 3																					72h PF-9927 activated CD8+		72h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290495	SRR10611223	9606	96h DMSO activated CD3+ rep 1																					96h DMSO activated CD3+		96h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290496	SRR10611224	9606	96h DMSO activated CD3+ rep 2																					96h DMSO activated CD3+		96h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290497	SRR10611225	9606	96h DMSO activated CD3+ rep 3																					96h DMSO activated CD3+		96h DMSO	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290498	SRR10611226	9606	96h PF-9927 activated CD3+ rep 1																					96h PF-9927 activated CD3+		96h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290499	SRR10611227	9606	96h PF-9927 activated CD3+ rep 2																					96h PF-9927 activated CD3+		96h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP235229	SRX7290500	SRR10611228	9606	96h PF-9927 activated CD3+ rep 3																					96h PF-9927 activated CD3+		96h PF-9927	peripheral blood																														Naive T lymphocytes		
SRP236876	SRX7347965	SRR10669490	9606	MLL-AF4_1 d4 DMSO																					CD34+ HSPCs from cord blood		DMSO			t(4;11)(q21;q23)																														
SRP236876	SRX7347966	SRR10669491	9606	MLL-AF4_1 d4 15µM																					CD34+ HSPCs from cord blood		15 µM PF-366			t(4;11)(q21;q23)																														
SRP236876	SRX7347967	SRR10669492	9606	MLL-AF4_2 d4 DMSO																					CD34+ HSPCs from cord blood		DMSO			t(4;11)(q21;q23)																														
SRP236876	SRX7347968	SRR10669493	9606	MLL-AF4_2 d4 15µM																					CD34+ HSPCs from cord blood		15 µM PF-366			t(4;11)(q21;q23)																														
SRP238361	SRX7422009	SRR10746625	9606	WT cell line RNA-seq replicate 1																					HCT116 stable cells																					HCT116								empty vector cell line				Colorectal carcinoma		
SRP238361	SRX7422010	SRR10746626	9606	WT cell line RNA-seq replicate 2																					HCT116 stable cells																					HCT116								empty vector cell line				Colorectal carcinoma		
SRP238361	SRX7422011	SRR10746627	9606	WT cell line RNA-seq replicate 3																					HCT116 stable cells																					HCT116								empty vector cell line				Colorectal carcinoma		
SRP238361	SRX7422012	SRR10746628	9606	WT T1-44 cell line RNA-seq replicate 1																					HCT116 stable cells																					HCT116								empty vector cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP238361	SRX7422013	SRR10746629	9606	WT T1-44 cell line RNA-seq replicate 2																					HCT116 stable cells																					HCT116								empty vector cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP238361	SRX7422014	SRR10746630	9606	WT T1-44 cell line RNA-seq replicate 3																					HCT116 stable cells																					HCT116								empty vector cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP238361	SRX7422015	SRR10746631	9606	E2F1Cr cell line RNA-seq replicate 1																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line				Colorectal carcinoma		
SRP238361	SRX7422016	SRR10746632	9606	E2F1Cr cell line RNA-seq replicate 2																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line				Colorectal carcinoma		
SRP238361	SRX7422017	SRR10746633	9606	E2F1Cr cell line RNA-seq replicate 3																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line				Colorectal carcinoma		
SRP238361	SRX7422018	SRR10746634	9606	E2F1Cr T1-44 cell line RNA-seq replicate 1																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP238361	SRX7422019	SRR10746635	9606	E2F1Cr T1-44 cell line RNA-seq replicate 2																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP238361	SRX7422020	SRR10746636	9606	E2F1Cr T1-44 cell line RNA-seq replicate 3																					HCT116 stable cells with E2F1 knockdown																					HCT116								E2F1 knockdown cell line treated with PRMT5 inhibitor	PRMT5 inhibitor treatment: 1uM, 48h			Colorectal carcinoma		
SRP249999	SRX7748807	SRR11111787	9606	RPHD7DMS																					T cells		RPHD7 T cells CD3/CD28 +DMSO																																	
SRP249999	SRX7748808	SRR11111788	9606	RPHD7 PRT																					T cells		RPHD7 T cells CD3/CD28 +PRMT5 INHIBITOR																																	
SRP249999	SRX7748809	SRR11111789	9606	RPHD17DM																					T cells		RPHD17 T cells CD3/CD28 +DMSO																																	
SRP249999	SRX7748810	SRR11111790	9606	RPHD17PR																					T cells		RPHD17 T cells CD3/CD28 +PRMT5 INHIBITOR																																	
SRP249999	SRX7748811	SRR11111791	9606	RPHD18DM																					T cells		RPHD18 T cells CD3/CD28 +DMSO																																	
SRP249999	SRX7748812	SRR11111792	9606	RPHD18PR																					T cells		RPHD18 T cells CD3/CD28 +PRMT5 INHIBITOR																																	
SRP249999	SRX7748813	SRR11111793	9606	RPHD19DM																					T cells		RPHD19 T cells CD3/CD28 +DMSO																																	
SRP249999	SRX7748814	SRR11111794	9606	RPHD19PR																					T cells		RPHD19 T cells CD3/CD28 +PRMT5 INHIBITOR																																	
SRP050943	SRX799449	SRR1696812	9606	esiGFP-r1																					Hela cells (cervical cancer cells)																					Hela										control esiRNA				
SRP050943	SRX799450	SRR1696813	9606	esiPRMT9-r1																					Hela cells (cervical cancer cells)																					Hela										esiRNA targeting PRMT9 (1ug esiRNA/10cm dish)				
SRP050943	SRX799451	SRR1696814	9606	esiGFP-r2																					Hela cells (cervical cancer cells)																					Hela										control esiRNA				
SRP050943	SRX799452	SRR1696815	9606	esiPRMT9-r2																					Hela cells (cervical cancer cells)																					Hela										esiRNA targeting PRMT9 (1ug esiRNA/10cm dish)				
SRP260446	SRX8287701	SRR11728467	9606	RNA-Seq-siCTL-HEK293																					HEK293		siCTL-HEK293	Human Embryonic Kidney																		HEK293														
SRP260446	SRX8287702	SRR11728468	9606	RNA-Seq-siPRMT4-HEK293																					HEK293		siPRMT4-HEK293	Human Embryonic Kidney																		HEK293														
SRP260446	SRX8287703	SRR11728469	9606	RNA-Seq-siPRMT5-HEK293																					HEK293		siPRMT5-HEK293	Human Embryonic Kidney																		HEK293														
SRP260446	SRX8287704	SRR11728470	9606	RNA-Seq-siPRMT7-HEK293																					HEK293		siPRMT7-HEK293	Human Embryonic Kidney																		HEK293														
SRP267712	SRX8567881	SRR12038075	9606	Melanoma, untreated, A0-2_S28																					Melanoma, untreated		untreated		BRAFV600E																	A375s														
SRP267712	SRX8567882	SRR12038076	9606	Melanoma, untreated, A0-3_S29																					Melanoma, untreated		untreated		BRAFV600E																	A375s														
SRP267712	SRX8567883	SRR12038077	9606	Melanoma, untreated, A0-4_S30																					Melanoma, untreated		untreated		BRAFV600E																	A375s														
SRP267712	SRX8567884	SRR12038078	9606	Melanoma, Verafinib, A20-1_S31																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	A375s														
SRP267712	SRX8567885	SRR12038079	9606	Melanoma, Verafinib, A20-2_S32																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	A375s														
SRP267712	SRX8567886	SRR12038080	9606	Melanoma, Verafinib, A20-3_S33																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	A375s														
SRP267712	SRX8567887	SRR12038081	9606	Melanoma, untreated, M0-1_S34																					Melanoma, untreated		untreated		BRAFV600E																	M14s														
SRP267712	SRX8567888	SRR12038082	9606	Melanoma, untreated, M0-2_S35																					Melanoma, untreated		untreated		BRAFV600E																	M14s														
SRP267712	SRX8567889	SRR12038083	9606	Melanoma, untreated, M0-3_S36																					Melanoma, untreated		untreated		BRAFV600E																	M14s														
SRP267712	SRX8567890	SRR12038084	9606	Melanoma, Verafinib, M20-1_S37																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	M14s														
SRP267712	SRX8567891	SRR12038085	9606	Melanoma, Verafinib, M20-2_S38																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	M14s														
SRP267712	SRX8567892	SRR12038086	9606	Melanoma, Verafinib, M20-3_S39																					Melanoma, Verafinib		2 µM Verafinib for 20 days		BRAFV600E																	M14s														
SRP268625	SRX8608945	SRR12081762	9606	HEK293T_PRMT-shScramble																					HEK293T cell line		Scramble shRNA control																			HEK293T														
SRP268625	SRX8608946	SRR12081763	9606	HEK293T_PRMT1-sh1																					HEK293T cell line		PRMT1 knockdown																			HEK293T														
SRP268625	SRX8608947	SRR12081764	9606	HEK293T_PRMT1-sh3																					HEK293T cell line		PRMT1 knockdown																			HEK293T														
SRP268625	SRX8608948	SRR12081765	9606	HEK293T_PRMT3-sh1																					HEK293T cell line		PRMT3 knockdown																			HEK293T														
SRP268625	SRX8608949	SRR12081766	9606	HEK293T_PRMT3-sh2																					HEK293T cell line		PRMT3 knockdown																			HEK293T														
SRP268625	SRX8608950	SRR12081767	9606	HEK293T_PRMT4-sh1																					HEK293T cell line		PRMT4 knockdown																			HEK293T														
SRP268625	SRX8608951	SRR12081768	9606	HEK293T_PRMT4-sh3																					HEK293T cell line		PRMT4 knockdown																			HEK293T														
SRP268625	SRX8608952	SRR12081769	9606	HEK293T_PRMT5-sh1																					HEK293T cell line		PRMT5 knockdown																			HEK293T														
SRP268625	SRX8608953	SRR12081770	9606	HEK293T_PRMT5-sh2																					HEK293T cell line		PRMT5 knockdown																			HEK293T														
SRP268625	SRX8608954	SRR12081771	9606	HEK293T_PRMT6-sh3																					HEK293T cell line		PRMT6 knockdown																			HEK293T														
SRP268625	SRX8608955	SRR12081772	9606	HEK293T_PRMT7-sh2																					HEK293T cell line		PRMT7 knockdown																			HEK293T														
SRP268625	SRX8608956	SRR12081773	9606	HEK293T_PRMT7-sh3																					HEK293T cell line		PRMT7 knockdown																			HEK293T														
SRP268628	SRX8609009	SRR12081852	9606	293T_DMSO_input											total input										HEK293T cell line		treated with DMSO																			HEK293T														
SRP268628	SRX8609010	SRR12081853	9606	293T_DMSO_1ribosome											bound with one ribosome (monosome)										HEK293T cell line		treated with DMSO																			HEK293T														
SRP268628	SRX8609011	SRR12081854	9606	293T_DMSO_2ribosome											bound with two ribosomes										HEK293T cell line		treated with DMSO																			HEK293T														
SRP268628	SRX8609012	SRR12081855	9606	293T_DMSO_3ribosome											bound with three or more ribosomes										HEK293T cell line		treated with DMSO																			HEK293T														
SRP268628	SRX8609013	SRR12081856	9606	293T_PRMT1-inhibitor_input											total input										HEK293T cell line		treated with PRMT1 inhibitor																			HEK293T														
SRP268628	SRX8609014	SRR12081857	9606	293T_PRMT1-inhibitor_1ribosome											bound with one ribosome (monosome)										HEK293T cell line		treated with PRMT1 inhibitor																			HEK293T														
SRP268628	SRX8609015	SRR12081858	9606	293T_PRMT1-inhibitor_2ribosome											bound with two ribosomes										HEK293T cell line		treated with PRMT1 inhibitor																			HEK293T														
SRP268628	SRX8609016	SRR12081859	9606	293T_PRMT1-inhibitor_3ribosome											bound with three or more ribosomes										HEK293T cell line		treated with PRMT1 inhibitor																			HEK293T														
SRP268628	SRX8609017	SRR12081860	9606	293T_PRMT4-inhibitor_input											total input										HEK293T cell line		treated with PRMT4 inhibitor																			HEK293T														
SRP268628	SRX8609018	SRR12081861	9606	293T_PRMT4-inhibitor_1ribosome											bound with one ribosome (monosome)										HEK293T cell line		treated with PRMT4 inhibitor																			HEK293T														
SRP268628	SRX8609019	SRR12081862	9606	293T_PRMT4-inhibitor_2ribosome											bound with two ribosomes										HEK293T cell line		treated with PRMT4 inhibitor																			HEK293T														
SRP268628	SRX8609020	SRR12081863	9606	293T_PRMT4-inhibitor_3ribosome											bound with three or more ribosomes										HEK293T cell line		treated with PRMT4 inhibitor																			HEK293T														
SRP271938	SRX8733843	SRR12223772	9606	Tu686_SiP5_1								siPRMT5-1													Tu686_siPRMT5																					Tu686												Epithelial-derived cells		
SRP271938	SRX8733844	SRR12223773	9606	Tu686_SiP5_2								siPRMT5-2													Tu686_siPRMT5																					Tu686												Epithelial-derived cells		
SRP271938	SRX8733845	SRR12223774	9606	Tu686_SiNC								siNC-1													Tu686_siNC																					Tu686												Epithelial-derived cells		
SRP271938	SRX8733846	SRR12223775	9606	SiNC_P5								siNC-2													Tu686_siNC																					Tu686												Epithelial-derived cells		
SRP273237	SRX8804971	SRR12301933	9606	22Rv1-shPRMT5-BR2-Dox-												BR2			shPRMT5						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804972	SRR12301934	9606	22Rv1-shPRMT5-BR2-Dox+												BR2			shPRMT5						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804973	SRR12301935	9606	22Rv1-shPRMT5-BR3-Dox-												BR3			shPRMT5						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804974	SRR12301936	9606	22Rv1-shPRMT5-BR3-Dox+												BR3			shPRMT5						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804975	SRR12301937	9606	22Rv1-shMEP50-BR1-Dox-												BR1			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804976	SRR12301938	9606	22Rv1-shMEP50-BR1-Dox+												BR1			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804977	SRR12301939	9606	22Rv1-shMEP50-BR2-Dox-												BR2			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804978	SRR12301940	9606	22Rv1-shMEP50-BR2-Dox+												BR2			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804979	SRR12301941	9606	22Rv1-shMEP50-BR3-Dox-												BR3			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804980	SRR12301942	9606	22Rv1-shMEP50-BR3-Dox+												BR3			shMEP50						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804981	SRR12301943	9606	22Rv1-shpICln-BR1-Dox-												BR1			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804982	SRR12301944	9606	22Rv1-shpICln-BR1-Dox+												BR1			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804983	SRR12301945	9606	22Rv1-shpICln-BR2-Dox-												BR2			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804984	SRR12301946	9606	22Rv1-shpICln-BR2-Dox+												BR2			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP273237	SRX8804985	SRR12301947	9606	22Rv1-shpICln-BR3-Dox-												BR3			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox -																
SRP273237	SRX8804986	SRR12301948	9606	22Rv1-shpICln-BR3-Dox+												BR3			shpICln						Human castration-resistant prostate cancer cells 22Rv1																			Dox +																
SRP275768	SRX8882101	SRR12383420	9606	MDA-MB-231-1-input																				human genome hg38	breast cancer cells		parental cells	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882102	SRR12383421	9606	MDA-MB-231-1-IP																				human genome hg38	breast cancer cells		parental cells	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882103	SRR12383422	9606	MDA-MB-231-2-input																				human genome hg38	breast cancer cells		parental cells	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882104	SRR12383423	9606	MDA-MB-231-2-IP																				human genome hg38	breast cancer cells		parental cells	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882105	SRR12383424	9606	MDA-MB-231-DOX11-input																				human genome hg38	breast cancer cells		parental cells treated with DOX	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882106	SRR12383425	9606	MDA-MB-231-DOX11-IP																				human genome hg38	breast cancer cells		parental cells treated with DOX	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882107	SRR12383426	9606	MDA-MB-231-DOX12-input																				human genome hg38	breast cancer cells		parental cells treated with DOX	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882108	SRR12383427	9606	MDA-MB-231-DOX12-IP																				human genome hg38	breast cancer cells		parental cells treated with DOX	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882109	SRR12383428	9606	MDA-MB-231-PRM75-DOX11-input																				human genome hg38	breast cancer cells		parental cells overexpressed with PRMT5 under DOX treatment	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882110	SRR12383429	9606	MDA-MB-231-PRM75-DOX11-IP																				human genome hg38	breast cancer cells		parental cells overexpressed with PRMT5 under DOX treatment	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882111	SRR12383430	9606	MDA-MB-231-PRM75-DOX12-input																				human genome hg38	breast cancer cells		parental cells overexpressed with PRMT6 under DOX treatment	breast cancer cells																		MDA-MB-231														
SRP275768	SRX8882112	SRR12383431	9606	MDA-MB-231-PRM75-DOX12-IP																				human genome hg38	breast cancer cells		parental cells overexpressed with PRMT6 under DOX treatment	breast cancer cells																		MDA-MB-231														
SRP276651	SRX8908663		9606	DDX5 KD rep 2 DRIP-seq																					Osteosarcoma				DDX5 KD						Monoclonal S9.6											U2OS														
SRP276651	SRX8908664		9606	DDX5 KD input DRIP-seq																					Osteosarcoma				DDX5 KD input						none											U2OS														
SRP276651	SRX8908665		9606	PRMT5 KD rep 1 DRIP-seq																					Osteosarcoma				PRMT5 KD						Monoclonal S9.6											U2OS														
SRP276651	SRX8908666		9606	PRMT5 KD rep 2 DRIP-seq																					Osteosarcoma				PRMT5 KD						Monoclonal S9.6											U2OS														
SRP276651	SRX8908667		9606	PRMT5 KD input DRIP-seq																					Osteosarcoma				PRMT5 KD input						none											U2OS														
SRP276651	SRX8908668		9606	XRN2 KD rep 1 DRIP-seq																					Osteosarcoma				XRN2 KD						Monoclonal S9.6											U2OS														
SRP276651	SRX8908669		9606	XRN2 KD rep 2 DRIP-seq																					Osteosarcoma				XRN2 KD						Monoclonal S9.6											U2OS														
SRP276651	SRX8908670		9606	XRN2 KD input DRIP-seq																					Osteosarcoma				XRN2 KD input						none											U2OS														
SRP276651	SRX8908671		9606	Control rep 1 RNA-seq																					Osteosarcoma				Control																	U2OS														
SRP276651	SRX8908672		9606	Control rep 2 RNA-seq																					Osteosarcoma				Control																	U2OS														
SRP276651	SRX8908673		9606	Control rep 3 RNA-seq																					Osteosarcoma				Control																	U2OS														
SRP276651	SRX8908674		9606	DDX5 KD rep 1 RNA-seq																					Osteosarcoma				DDX5 KD																	U2OS														
SRP276651	SRX8908675		9606	DDX5 KD rep 2 RNA-seq																					Osteosarcoma				DDX5 KD																	U2OS														
SRP276651	SRX8908676		9606	DDX5 KD rep 3 RNA-seq																					Osteosarcoma				DDX5 KD																	U2OS														
SRP276651	SRX8908677		9606	PRMT5 KD rep 1 RNA-seq																					Osteosarcoma				PRMT5 KD																	U2OS														
SRP276651	SRX8908678		9606	PRMT5 KD rep 2 RNA-seq																					Osteosarcoma				PRMT5 KD																	U2OS														
SRP276651	SRX8908679		9606	PRMT5 KD rep 3 RNA-seq																					Osteosarcoma				PRMT5 KD																	U2OS														
SRP276651	SRX8908680		9606	XRN2 KD rep 1 RNA-seq																					Osteosarcoma				XRN2 KD																	U2OS														
SRP276651	SRX8908681		9606	XRN2 KD rep 2 RNA-seq																					Osteosarcoma				XRN2 KD																	U2OS														
SRP276651	SRX8908682		9606	XRN2 KD rep 3 RNA-seq																					Osteosarcoma				XRN2 KD																	U2OS														
SRP276681	SRX8910013	SRR12413842	9606	CON RNA-seq																					Tu212 cells				control																	Tu212												Epithelial-derived cells		
SRP276681	SRX8910014	SRR12413843	9606	PRMT5 RNA-seq																					Tu212 cells				PRMT5 overexpression																	Tu212												Epithelial-derived cells		
SRP285543	SRX9199738	SRR12721015	9606	A549 GSK591 7 days Rep1																					A549		GSK591																			A549												epithelial		
SRP285543	SRX9199739	SRR12721016	9606	A549 GSK591 7 days Rep2																					A549		GSK591																			A549												epithelial		
SRP285543	SRX9199740	SRR12721017	9606	A549 GSK591 7 days Rep3																					A549		GSK591																			A549												epithelial		
SRP285543	SRX9199741	SRR12721018	9606	A549 MS023 7 days Rep1																					A549		MS023																			A549												epithelial		
SRP285543	SRX9199742	SRR12721019	9606	A549 MS023 7 days Rep2																					A549		MS023																			A549												epithelial		
SRP285543	SRX9199743	SRR12721020	9606	A549 MS023 7 days Rep3																					A549		MS023																			A549												epithelial		
SRP285543	SRX9199744	SRR12721012	9606	A549 DMSO 7 days Rep1																					A549		DMSO																			A549												epithelial		
SRP285543	SRX9199745	SRR12721013	9606	A549 DMSO 7 days Rep2																					A549		DMSO																			A549												epithelial		
SRP285543	SRX9199746	SRR12721014	9606	A549 DMSO 7 days Rep3																					A549		DMSO																			A549												epithelial		
